Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-07-17
2007-07-17
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S317000
Reexamination Certificate
active
11303633
ABSTRACT:
Impairments in memory consolidation are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound. The method can include determining memory consolidation before, during and/or after administering the amphetamine compound.
REFERENCES:
patent: 2828343 (1958-03-01), Tindall
patent: 3728445 (1973-04-01), Bardani
patent: 3996381 (1976-12-01), Florvall et al.
patent: 4034113 (1977-07-01), Shulgin
patent: 4105695 (1978-08-01), Partyka et al.
patent: 4479932 (1984-10-01), Bodor
patent: 4598094 (1986-07-01), Wurtman et al.
patent: 4636494 (1987-01-01), Growdon et al.
patent: 4647591 (1987-03-01), Cherkin et al.
patent: 5019594 (1991-05-01), Wurtman et al.
patent: 5075338 (1991-12-01), Knoll et al.
patent: 5096712 (1992-03-01), Wurtman
patent: 5151449 (1992-09-01), Milgram
patent: 5220068 (1993-06-01), Knoll et al.
patent: 5225446 (1993-07-01), Milgram
patent: 5422355 (1995-06-01), White et al.
patent: 5684018 (1997-11-01), Alexander
patent: 5914129 (1999-06-01), Mauskop
patent: 6204245 (2001-03-01), Siegel et al.
patent: 6228875 (2001-05-01), Tsai et al.
patent: 6251938 (2001-06-01), Chorev et al.
patent: 6284760 (2001-09-01), Marston et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6492427 (2002-12-01), Shankar et al.
patent: 6635675 (2003-10-01), Kranzler et al.
patent: 2002/0066457 (2002-06-01), Landfield et al.
patent: 2 108 032 (1972-05-01), None
patent: 2 122 617 (1984-01-01), None
patent: WO 97/17067 (1997-05-01), None
patent: WO 97/26871 (1997-07-01), None
patent: WO 99/16746 (1999-04-01), None
patent: WO 00/01379 (2000-01-01), None
patent: WO 00/32556 (2000-06-01), None
patent: WO 00/59479 (2000-10-01), None
patent: WO 01/09897 (2001-02-01), None
patent: WO 02/053104 (2002-07-01), None
Muller et al., J. Clin. Physchology (1997) V. 53(7) 663-671.
Goodman and Gilmans' The Pharmacological basis of Therapeutics (Goodman et al.). 9thEdition pp. 202 and 221 (total pp. 4).
Yasar, S., et al., “Preclinical Evaluation ofl-Deprenyl: Lack of Amphetamine-Like Abuse Potential,”Inhibitors of Monoamine Oxidase B Pharmacology and Clinical Uses in Neurodegenerative Disorders, I. Szelenyi, ed. (Switzerland: Birkhauser Verlag Basel), pp. 215-233 (1993).
Yasar, S. and Bergman, J., “Amphetamine-like effect ofl-deprenyl (selegiline) in Drug Discrimination Studies,”Clin. Pharmacol. Ther., 56(6):768-773 (1994).
Shappell, S. A., et al., “Stimulated Sustained Flight Operations and Performance, Part 2: Effects of Dextro-Methamphetamine,”Military Psychology, 4(4), 267-287 (2002).
Cook, C. E., et al., “Pharmacokinetics of Methamphetamine Self-Administered to Human Subjects by Smoking S-(+)-Methamphetamine Hydrochloride,”Drug Metab. Dispos., 21(4): 717-723 (1993).
Vorhees, C. V., et al., “Adult Learning Deficits After Neonatal Exposure to D-Methamphetamine: Selective Effects on Spatial Navigation and Memory,”J. Neurosc., 20(12): 4732-4739 (2000).
Mann, J. J., et al., “A Controlled Study of the Antidepressant Efficacy and Side Effects of(−)-Deprenyl,”Arch. Gen. Psychiatry, 46: 45-50 (1989).
Kohl, R. L. et al., “Arousal and Stability: The Effects of five New Sympathomimetic Drugs Suggest a New Principle for the Prevention of Space Motion Sickness,”Aviat. Space, Environ. Med., 137-143 (1986).
Wang, J. Q. and McGinty, J. F., “Dose-Dependent Alteration inzifl268 and Preprodynorphin mRNA Expression Induced by Amphetamine or Methamphetamine in Rat Forebrain,”J. Pharmacol. Exp. Ther., 273(2): 909-917 (1995).
Melega, W. P., et al., “Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal,”J. Pharmacol. Exp. Ther., 274(1): 90-96 (1995).
Bisagno, V., et al., “Short Toxic Methamphetamine Schedule Impairs Object Recognition Task in Male Rats,”Brain Res., 940: 95-101 (2002).
Yamamoto, R., and Takasaki, K., “Involvement of Presynaptica2-Adrenoreceptors in the Depressor Response Produced by Repeated Administration of Dextro-Methamphetamine,”J. Auton. Pharmac., 3: 79-88 (1983).
Cappon, G. D. and Vorhees, C. V., “Plasma and Brain Methamphetamine Concentrations in Neonatal Rats,”Neurotoxicol. Teratol., 23: 81-88 (2001).
Gyarmati, Z. S., et al., “Behavioural Consequences of Methamphetamine-Induced Neurotoxicity in Rats,”Neurobiology, 9(1): 37-39 (2001).
Riviere, G. J., et al., “Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat,”J. Pharmacol. Exp. Ther., 291(3): 1220-1226 (1999).
Haughey, H. M., et al., “Differential Effects of Methamphetamine on NA+/CI−Dependent Transporters,”Brain Res., 863: 59-65 (2000).
Caldwell, J., et al., “Metabolism of [14C]Methamphetamine in Man, the Guinea Pig and the Rat,”Biochem. J., 129: 11-22 (1972).
Chapman, D. E., et al., “Long-Term Changes in Basal Ganglia Function After a Neurotoxic Regimen of Methamphetamine,”J. Pharmacol.Exp. Ther., 296(2): 520-527 (2001).
Melega, W. P., et al., “Effects of Deprenyl Metabolite, L-Methamphetamine on Striatal Dopamine Efflux,”Neurotransmission, Neuromodulation, A376, Abstract No. 2177.
Lin, L. Y., et al., “Cytochrome P4502D Isozymes Catalyze the 4-Hydroxylation of Methamphetamine Enantiomers,”Drug Metab. Dispos., 23(6): 610-614 (1995).
Yanagisawa, Y., et al., Association Equilibrium ofd-Methamphetamine andl-Methamphetamine With Serum Albumin,Chirality 10: 742-746 (1998).
Melega, W. P., et al.,l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of in vivo Deprenyl-Derivedl-Methamphetamine,J.Pharmacol. Exp. Ther., 288(2): 752-758 (1999).
Yokel, R. A. and Pickens, R., “Self-Administration of Optical Isomers of Amphetamine and Methylamphetamine by Rats,”J. Pharmacol. Exp. Ther., 187(1): 27-33 (1973).
Ozaki, T., et al., “The Adverse Effects ofI-Methamphetamine on the Development of Explanted Rat Embryos,”Asia-Oceania Journal Obstet. Gynaecol.18(3): 277-281 (1992).
Vidrio, H., “Cardiovascular Effects of Methamphetamine in Dogs Treated Chronically with the Amine,”J. Cardiovas. Pharmacol., 4(2): 326-329 (1982).
Roth, L. W., et al., “A Comparison of the Analeptic, Circulatory and Other Properties of D- and L- Desoxyephedrine,”Arch. Int. Pharmacoyn., XCVII(3): 362-368 (1954).
Lehmann, H. E. and Ban, T. A., “Effects of Psychoactive Drugs on Conflict Avoidance Behavior in Human Subjects,”Activitas nervosa superior, 13(2): 82-85 (1971).
Matthews, C., “Overweight Relapse: Effects of Training and Methamphetamine with Pentobarbital,”Curr. Ther. Res., 12(1): 34-39 (1970).
Martin, W. R., et al., “Physiologic, Subjective, and Behavioral Effects of Amphetamine, Methamphetamine, Ephedrine, Phenmetrazine, and Methylphenidate in Man,”Clin. Pharmacol. Ther., 12(2): 245-258 (1970).
Shimosato, K., “Urinary Excretion ofp-Hydroxylated Methamphetamine Metabolites in Man. II. Effect of Alcohol Intake on Methamphetamine Metabolism,”Pharmacol. Biochem. Behav., 29: 733-740 (1988).
Cookson, J. and Silverstone, T., “The Effects of Methamphetamine on Mood and Appetite in Depressed Patients: A Placebo-controlled Study,”Int. Clin. Psychopharmacol., 1: 127-133 (1986).
Sim, T., et al., “Cognitive Deficits Among Methamphetamine Users with Attention Deficit Hyperactivity Disorder Symptomatology,”J. Addict. Dis., 21(1): 75-89 (2002).
Comer, S. D., et al., “Effects of Repeated Oral Methamphetamine Administration in Humans,”Psychopharmacology, 155: 397-404 (2001).
Mohs, R. C., et al., “Sensitivity of Some Human Cognitive Functions to Effects of Methamphetamine and Secobarbital,”Drug and Alcohol Depend., 5: 145-150 (1980).
Mohs, R. C., et al., “Metham
Epstein Mel H.
Wiig Kjesten A.
Cognition Pharmaceuticals LLC
Gembeh Shirley V.
Hamilton Brook Smith & Reynolds P.C.
Marschel Ardin H.
LandOfFree
Methods for treating an impairment in memory consolidation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating an impairment in memory consolidation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating an impairment in memory consolidation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731152